620116-57-6

Basic information

• Product Name: (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester
• Synonyms: (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester
• CAS NO: 620116-57-6
• Molecular Weight: 496.471
• Mol File: 620116-57-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester(620116-57-6)
• EPA Substance Registry System: (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester(620116-57-6)

Safety Data

• Hazardous Substances Data: 620116-57-6(Hazardous Substances Data)

Upstream product

• 620116-56-5 (5S,5aS,8aR,9R)-5-(Dimethyl-phenyl-silanyl)-8-oxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester 
• 620116-55-4 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-(3,4,5-trimethoxy-phenoxythiocarbonyloxymethyl)-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 
• 620116-51-0 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-((S)-4-isopropyl-4,5-dihydro-oxazol-2-yl)-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 
• 620116-54-3 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-hydroxymethyl-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 
• 620116-53-2 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-formyl-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 

Downstream Products

• 55515-07-6 (1α,2α,3α)-podophyllotoxin 

Relevant articles and documents

The intramolecular carboxyarylation approach to podophyllotoxin

Since 1960, only seven plant-derived anticancer drugs have received FDA approval for commercial production. Two are semisynthetic derivatives of podophyllotoxin. This paper describes concise, highly convergent, and conceptually novel approaches to (-)-pod